Administering fibrosis-free EVs to mice with CCL4-induced liver injury has been shown to suppress hepatocellular damage and liver fibrosis, reducing the number of inflammatory cytokines and transaminases in the blood. Here, CCL4 is linked to Hepatic fibrosis.